Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up

MLA

Roberto Piro, et al. “Clinical and Pharmacoeconomic Aspects of Omalizumab: A 4-Year Follow-Up.” Therapeutic Advances in Respiratory Disease, vol. 6, Feb. 2012, pp. 87–95. EBSCOhost, https://doi.org/10.1177/1753465811429478.

APA

Roberto Piro, Nicola Facciolongo, Debora Formisano, Cristiano Carbonelli, Anna Simonazzi, Luigi Zucchi, A. Roggeri, Claudia Castagnetti, & Francesco Menzella. (2012). Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Therapeutic Advances in Respiratory Disease, 6, 87–95. https://doi.org/10.1177/1753465811429478

Chicago

Roberto Piro, Nicola Facciolongo, Debora Formisano, Cristiano Carbonelli, Anna Simonazzi, Luigi Zucchi, A. Roggeri, Claudia Castagnetti, and Francesco Menzella. 2012. “Clinical and Pharmacoeconomic Aspects of Omalizumab: A 4-Year Follow-Up.” Therapeutic Advances in Respiratory Disease 6 (February): 87–95. doi:10.1177/1753465811429478.